A study has now shown that copper ions can drive inflammation via a mitochondrial signaling pathway that regulates epigenetic states of immune cells. This pathway could offer a new route for treating inflammatory diseases.
This is a preview of subscription content, log in via an institution to check access.
References
Furman, D. et al. Nat. Med. 25, 1822–1832 (2019).
Ge, E. J. et al. Nat. Rev. Cancer 22, 102–113 (2022).
Hodgkinson, V. & Petris, M. J. J. Biol. Chem. 287, 13549–13555 (2012).
Solier, S. et al. Nature 617, 386–394 (2023).
Natoli, G., Pileri, F., Gualdrini, F. & Ghisletti, S. EMBO Rep. 22, e53251 (2021).
Chang, C. J. Nat. Chem. Biol. 11, 744–747 (2015).
Tsang, T., Davis, C. I. & Brady, D. C. Curr. Biol. 31, R421–R427 (2021).
Campbell, S. L. & Wellen, K. E. Mol. Cell 71, 398–408 (2018).
Ramchandani, D. et al. Nat. Commun. 12, 7311 (2021).
Tsvetkov, P. et al. Science 375, 1254–1261 (2022).
Cotruvo, J. A. Jr, Aron, A. T., Ramos-Torres, K. M. & Chang, C. J. Chem. Soc. Rev. 44, 4400–4414 (2015).
Ackerman, C. M., Lee, S. & Chang, C. J. Anal. Chem. 89, 22–41 (2017).
Pezacki, A. T. et al. Proc. Natl Acad. Sci. USA 119, e2202736119 (2022).
Pham, V. N. & Chang, C. J. Angew. Chem. Int. Ed. Engl. https://doi.org/10.1002/anie.202213644 (2023).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
D.C.B. holds ownership in Merlon Inc. and Elaeis Therapeutics, and is an inventor on patent application US 20150017261 entitled “Methods of treating and preventing cancer by disrupting the binding of copper in the MAP kinase pathway.” C.J.C. declares no competing interests.
Rights and permissions
About this article
Cite this article
Chang, C.J., Brady, D.C. Capturing copper to inhibit inflammation. Nat Chem Biol 19, 937–939 (2023). https://doi.org/10.1038/s41589-023-01383-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-023-01383-6
- Springer Nature America, Inc.